Welcome to our dedicated page for MERIT MEDICAL SYSTEMS SEC filings (Ticker: MMSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Merit Medical Systems Inc. filings document operating and financial results, Regulation FD disclosures and material events for a medical-device manufacturer serving interventional, diagnostic and therapeutic markets. Recent Form 8-K reports cover quarterly and annual results, conference-call materials, historical revenue information under the Foundational and Therapeutic product categories, and product-related updates.
The company’s proxy materials describe board composition, governance practices, executive compensation and shareholder voting matters. Other filed event reports address board-leadership changes, completed product-technology acquisitions, capital-structure disclosure categories and clinical or regulatory disclosures tied to Merit’s device portfolio.
MERIT MEDICAL SYSTEMS INC (symbol: MMSI) is the issuer of record for a Form 4 filing submitted to the SEC. Lewis Sheri reported acquisition or exercise transactions in this Form 4 filing.
MERIT MEDICAL SYSTEMS INC (MMSI) reported that Sheri Lewis, EVP of Global Operations, received a grant of 8,371 restricted stock units (RSUs) of common stock on September 4, 2026 under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan. The RSUs vest in three equal annual installments on each anniversary of the award date, subject to her continued service, and her directly held common stock position reported after this grant is 8,371 shares.
MERIT MEDICAL SYSTEMS INC (MMSI) filed an initial insider ownership report for Sheri Lewis, who serves as EVP of Global Operations. This Form 3 filing establishes her status as a company officer subject to SEC insider reporting rules. No equity holdings or transactions are detailed in this filing.
MERIT MEDICAL SYSTEMS INC (MMSI) reported that Chief Operating Officer Neil W. Peterson sold 7,500 shares of common stock on 2026-08-24 in an open-market transaction at a weighted average price of $90.448 per share, with individual trades ranging from $90.43 to $90.53. Following this sale, he directly holds 18,051 common shares. He also holds non-qualified stock options covering 25,000 underlying shares at an exercise price of $68.33, vesting in 25% annual installments beginning 08/19/2022, and options over 13,576 underlying shares at an exercise price of $70.58, vesting in 25% annual installments beginning 02/28/2024.
MERIT MEDICAL SYSTEMS INC (MMSI) executive Michel J. Voigt, Chief Human Resources Officer, reported a bona fide charitable gift of 650 shares of common stock on 2026-08-24, for no consideration. Following this gift, Voigt directly holds 45,412 common shares and indirectly holds 2,265 shares through a 401(k) plan. Voigt also holds non-qualified stock options over 2,420, 4,046, and 11,076 underlying common shares at exercise prices of $56.25, $65.03, and $70.58, expiring in 2028, 2029, and 2030, respectively.
MERIT MEDICAL SYSTEMS, INC. (MMSI) is the issuer of common stock covered by this notice of proposed sale under Rule 144. Officer Neil W. Peterson plans to sell 7,500 shares of MMSI common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $678,360.00 and 59,710,420 shares outstanding. The approximate date of sale is 08/24/2026. The 7,500 shares were acquired on 03/06/2024 from the issuer as exercised shares for cash. Over the past three months, Peterson has sold 21,449 shares of MMSI common stock for $1,823,165.00.
Merit Medical Systems, Inc. (MMSI) reported a leadership transition in its global operations organization and related executive employment terms. On August 14, 2026, Merit eliminated the Chief Operating Officer role, changing Neil W. Peterson’s title to Senior Advisor; he has given notice to resign as an employee effective March 5, 2027.
Effective August 31, 2026, Merit appointed Sheri Lewis as Executive Vice President of Global Operations. Her employment agreement provides a $600,000 annual base salary, a $400,000 signing bonus, and eligibility for an annual bonus starting in fiscal 2026 with a 60% of base salary target (pro-rated for 2026) and a 200% of base salary maximum, plus participation in the 2026 Equity Incentive Plan.
If Lewis is terminated without cause or resigns for good reason (outside a change of control), she is entitled to Accrued Obligations and a lump sum equal to the greater of one year of base salary or a formula based on her three-week salary rate multiplied by completed years of service (capped at 26 years), along with pro-rated performance stock units. If such a termination occurs in connection with a change of control, she instead receives Accrued Obligations and a lump sum equal to 2x the sum of her then-current base salary and the average of her bonuses for the prior three full fiscal years, plus vesting of target performance stock units.
Merit Medical Systems' chief operating officer Neil W. Peterson reported selling 21,449 shares of common stock on 2026-08-04 at $85.00 per share, leaving 25,551 shares held directly. He also reports non-qualified stock options on 25,000 shares at a $68.33 exercise price and 13,576 shares at $70.58, vesting in 25% annual installments beginning 08/19/2022 and 02/28/2024, respectively.
An affiliate of MMSI has filed a notice of proposed sale of common stock under Form 144. The filing lists up to 21,449 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with trading expected on the NASDAQ on or after August 4, 2026.
The shares relate to equity awards described as Performance Shares and Restricted Stock with grant dates in 2025 and 2026 and individual award amounts of 7,278, 1,027, 10,941, 1,175, and 1,028 shares, respectively.
Merit Medical Systems reported solid growth for the quarter and first half of 2026. Net sales reached $418.8 million for Q2 and $800.7 million year-to-date, up 9.5% and 8.5% from 2025. Gross profit margin improved to 51.4% in Q2, lifting income from operations to $60.4 million. Net income was $38.8 million for Q2 and $79.8 million for the first six months, with diluted EPS of $0.65 and $1.33, respectively.
Foundational products generated $281.0 million of Q2 revenue and therapeutic products $137.9 million, with strong growth in cardiac therapies and endoscopy platforms. Merit completed the View Point Medical acquisition for $137.3 million net of cash, following earlier Biolife and C2 CryoBalloon deals, and sold the DualCap product line for $28 million, recording a $12.5 million gain. Cash and cash equivalents were $448.7 million, with $736.3 million of convertible notes outstanding and no borrowings under the $700 million revolving credit facility.
Merit Medical Systems, Inc. reported strong second-quarter 2026 results, with net sales of $418.843 million, up 10% year-over-year and 9% on a constant currency basis. Management highlighted 9% organic, constant currency revenue growth excluding a strategic divestiture and 10% growth in U.S. sales. GAAP gross margin improved to 51.4% and non-GAAP gross margin to 55.8%. GAAP net income was $38.8 million ($0.65 per diluted share), while non-GAAP net income was $71.3 million ($1.19 per share), an 18% year-over-year increase.
GAAP operating margin rose to 14.4% and non-GAAP operating margin to 22.6%. For the first six months, free cash flow was $76.6 million. As of June 30, 2026, the company held $448.7 million in cash and cash equivalents, total debt obligations of $747.5 million, and approximately $697 million of available borrowing capacity.
Merit raised its full-year 2026 outlook, now guiding total revenue to $1.631–$1.643 billion (7.6–8.4% growth) and non-GAAP earnings per share to $4.25–$4.35, implying 11–14% growth, compared with prior EPS guidance of $4.01–$4.15. Management continues to target its three-year Continued Growth Initiative financial objectives through 2026.